药学

药学主要研究药物的来源、炮制、性状、作用、分析、鉴定、调配、生产、保管和寻找（包括合成）新药等。将健康科学与制药科学联系在一起，旨在追求安全、有效和平价的药物。 Enago在药学领域具有深厚的专业知识储备，拥有药学和相关学科，如药学数学与生物统计学、医药生物技术等相关学科的学科专业翻译师、双语校对以及英语母语学科专家编辑，且已翻译了大量此领域相关的科研论文，并协助诸多学术作者成功在国际知名SCI/EI/SSCI期刊上发表高水平论文。

研究目的：非诺贝特联合他汀类药物是目前临床指南高度推荐的混合性血脂异常的治疗药物。在本研究中，我们制备了一种创新的非诺贝特缓释制剂，以达到以下目的：通过改变非诺贝特的药代动力学特征来降低（同时给予这种联合疗法引起的）肌肉毒性的风险，并提高该缓释制剂的口服生物利用度。

研究方法：将非诺贝特微粉化，通过粉末分层法制备载药芯，然后进行多粒子包衣。研究筛选了不同的包衣配方，并与市售缓释微丸Lipilfen®的体外释放谱进行比较。在比格犬身上评估了两种优化的配方，并与非诺贝特的两种参比商业制剂（速释制剂Lipanthyl®和缓释微丸Lipilfen®）进行比较。

研究结果：非诺贝特在从体外试验选择的R1和R2的体内释放呈现滞后阶段，之后进行快速完全的药物释放。R1和R2的相对生物利用度分别为100.4%和201.1%，高于Lipilfen®（67.2%）。

研究结论：改良非诺贝特显示出增强的生物利用度和缓释性，并在与他汀类药物联合使用时可潜在地提高安全性和依从性。据我们所知，这是第一个关于非诺贝特缓释制剂的研究报告。

学科专家翻译：精于您论文领域的翻译师翻译，用语精准

Purpose: Fenofibrate and statin combination therapy is highly recommended by the current clinical guidelines for treatment of combined dyslipidemia. In this study, an innovative delayed-release preparation of fenofibrate was designed to reduce the risk of muscle toxicity, caused by simultaneous administration of this combination therapy, by altering the pharmacokinetic profile of fenofibrate, as well as to improve the oral bioavailability of the modified-release formulation.

Methods: Micronized fenofibrate was used to prepare drug-loaded cores via a powder layering process before multiparticulate pellet coating. Different coating formulations were screened, and their in vitro release was compared with the commercial sustained-release pellets Lipilfen®. Two optimized formulations were evaluated in Beagle dogs using two commercial preparations of fenofibrate (the immediate release preparation Lipanthyl® and the sustained release pellets Lipilfen®) as references.

Results: The in vivo release of fenofibrate from R1 and R2 selected from in vitro tests exhibited a lag phase, and then rapid and complete drug release. The relative bioavailabilities of R1 and R2 were 100.4% and 201.1%, respectively, which were greater than that of Lipilfen® (67.2%).

Conclusion: The modified fenofibrate pellets developed enhanced bioavailability and delayed-release properties. They have the potential to improve safety and compliance when co-administrated with statins. This is the first report of a delayed-release fenofibrate preparation.

质量控制确认后，译稿送交给客户

Purpose: According to current guidelines.combination therapy of fenofibrate and statins is highly recommended for treating mixed dyslipidemia. In this study, we formulated an innovative delayed-release preparation of fenofibrate to reduce the risk of muscle toxicity, by altering the pharmacokinetic profile of fenofibrate and to improve the oral bioavailability of the modified-release formulation.

Methods: Fenofibrate was micronized and used to prepare drug-loaded cores via a powder-layering process before performing multiparticulate pellet coating. Different coating formulations were screened, and their in vitro release profiles were compared with those of the commercial sustained-release pellets Lipilfen®. Two optimized formulations were evaluated in Beagle dogs models and compared with two reference commercial preparations of fenofibrate, Lipanthyl®(the immediate-release preparation) and Lipilfen®(the sustained- release pellets) .

Results: The in vivo release of fenofibrate from R1 and R2 (selected from in vitro tests) exhibited a lag phase, which was followed by rapid and complete drug release. The relative bioavailabilities of R1 and R2 were 100.4% and 201.1%, respectively, which werehigher than that of Lipilfen® (67.2%).

Conclusion: Modified fenofibrate pellets showed enhanced bioavailability and delayed-release propertiesand can improve safety and compliance when co-administered with statins. To the best of our knowledge, this is the first report of a delayed-release preparation of fenofibrate.